• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The "Traditional Chinese medicine regulating liver regeneration" treatment plan for reducing mortality of patients with hepatitis B-related liver failure based on real-world clinical data.基于真实世界临床数据的“中医调控肝再生”治疗方案降低乙肝相关肝衰竭患者死亡率的研究
Front Med. 2021 Jun;15(3):495-505. doi: 10.1007/s11684-020-0790-9. Epub 2021 Jan 12.
2
Clinical trial with traditional Chinese medicine intervention ''tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment'' for chronic hepatitis B-associated liver failure.中药干预“补肾通过影响干细胞及其微环境促进肝再生与修复”治疗慢性乙型肝炎相关肝衰竭的临床试验
World J Gastroenterol. 2014 Dec 28;20(48):18458-65. doi: 10.3748/wjg.v20.i48.18458.
3
[A prospective cohort study on the influence of high doses of herbs for clearing heat and resolving stasis on survival rates in patients with hepatitis B-related acute-on-chronic liver failure].[一项关于大剂量清热化瘀中药对乙型肝炎相关慢加急性肝衰竭患者生存率影响的前瞻性队列研究]
Zhong Xi Yi Jie He Xue Bao. 2012 Feb;10(2):176-85. doi: 10.3736/jcim20120208.
4
Clinical effects of combined treatment of traditional Chinese medicine and western medicine for viral hepatitis B cirrhosis and the effects on serum miR-122, miR-200a.中药联合西药治疗乙型肝炎肝硬化的临床疗效及对血清 miR-122、miR-200a 的影响
Biotechnol Genet Eng Rev. 2024 Nov;40(3):2803-2817. doi: 10.1080/02648725.2023.2202531. Epub 2023 Apr 14.
5
Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula.中药复方抗肝纤维化治疗的研究进展。
J Ethnopharmacol. 2020 Apr 6;251:112442. doi: 10.1016/j.jep.2019.112442. Epub 2019 Dec 28.
6
Short-term efficacy of treating hepatitis B virus-related acute-on-chronic liver failure based on cold pattern differentiation with hot herbs: A randomized controlled trial.基于寒证辨治采用温热药治疗乙型肝炎病毒相关慢加急性肝衰竭的短期疗效:一项随机对照试验
Chin J Integr Med. 2016 Aug;22(8):573-80. doi: 10.1007/s11655-016-2582-2. Epub 2016 May 24.
7
Therapeutic effect of traditional Chinese medicine on coagulation disorder and accompanying intractable jaundice in hepatitis B virus-related liver cirrhosis patients.中药对乙型肝炎病毒相关性肝硬化患者凝血功能障碍及伴发的顽固性黄疸的治疗作用
World J Gastroenterol. 2008 Oct 21;14(39):6060-4. doi: 10.3748/wjg.14.6060.
8
[Auxiliary treatment of HBV correlated hepatic failure by Chinese herbs: a systematic review of randomized controlled trials].中药辅助治疗乙肝相关性肝衰竭:随机对照试验的系统评价
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Nov;33(11):1449-56.
9
[Study on chronical hepatitis B with treatment of integrative traditional Chinese and Western medicine].[中西医结合治疗慢性乙型肝炎的研究]
Zhongguo Zhong Yao Za Zhi. 2006 Aug;31(15):1277-80.
10
[Systematic review and meta-analysis of randomized controlled trials of integrative medicine therapy for treatment of chronic severe hepatitis].[中西医结合疗法治疗慢性重型肝炎的随机对照试验的系统评价与Meta分析]
Zhong Xi Yi Jie He Xue Bao. 2012 Nov;10(11):1211-28. doi: 10.3736/jcim20121104.

引用本文的文献

1
Pretreatment of artesunate promoted hepatocyte proliferation by activating the PI3K/Akt/mTOR signaling pathway in mice.青蒿琥酯预处理通过激活 PI3K/Akt/mTOR 信号通路促进小鼠肝细胞增殖。
Acta Cir Bras. 2024 Oct 25;39:e394324. doi: 10.1590/acb394324. eCollection 2024.

本文引用的文献

1
Curcumin and Curcuma longa L. extract ameliorate lipid accumulation through the regulation of the endoplasmic reticulum redox and ER stress.姜黄素和姜黄提取物通过调节内质网氧化还原和内质网应激改善脂质积累。
Sci Rep. 2017 Jul 26;7(1):6513. doi: 10.1038/s41598-017-06872-y.
2
A hot water extract of turmeric () suppresses acute ethanol-induced liver injury in mice by inhibiting hepatic oxidative stress and inflammatory cytokine production.姜黄的热水提取物通过抑制肝脏氧化应激和炎性细胞因子的产生来抑制小鼠急性乙醇诱导的肝损伤。
J Nutr Sci. 2017 Jan 12;6:e3. doi: 10.1017/jns.2016.43. eCollection 2017.
3
Neuroprotective Effect of Paeonol Mediates Anti-Inflammation via Suppressing Toll-Like Receptor 2 and Toll-Like Receptor 4 Signaling Pathways in Cerebral Ischemia-Reperfusion Injured Rats.丹皮酚对脑缺血再灌注损伤大鼠的神经保护作用通过抑制Toll样受体2和Toll样受体4信号通路介导抗炎反应。
Evid Based Complement Alternat Med. 2016;2016:3704647. doi: 10.1155/2016/3704647. Epub 2016 Dec 22.
4
Real-World Evidence - What Is It and What Can It Tell Us?真实世界证据——它是什么以及能告诉我们什么?
N Engl J Med. 2016 Dec 8;375(23):2293-2297. doi: 10.1056/NEJMsb1609216.
5
Schisandra polysaccharide inhibits hepatic lipid accumulation by downregulating expression of SREBPs in NAFLD mice.五味子多糖通过下调非酒精性脂肪性肝病(NAFLD)小鼠中固醇调节元件结合蛋白(SREBPs)的表达来抑制肝脏脂质积累。
Lipids Health Dis. 2016 Nov 16;15(1):195. doi: 10.1186/s12944-016-0358-5.
6
Upregulation of toll-like receptor 4 on T cells in PBMCs is associated with disease aggravation of HBV-related acute-on-chronic liver failure.外周血单个核细胞中T细胞上Toll样受体4的上调与乙型肝炎病毒相关慢加急性肝衰竭的疾病加重有关。
J Huazhong Univ Sci Technolog Med Sci. 2015 Dec;35(6):910-915. doi: 10.1007/s11596-015-1527-x. Epub 2015 Dec 16.
7
Promoter methylation status and expression of PPAR-γ gene are associated with prognosis of acute-on-chronic hepatitis B liver failure.PPAR-γ基因的启动子甲基化状态及表达与慢性乙型肝炎急性肝衰竭的预后相关。
Clin Epigenetics. 2015 Oct 28;7:115. doi: 10.1186/s13148-015-0149-2. eCollection 2015.
8
Corticosteroid and nucleoside analogue for hepatitis B virus-related acute liver failure.用于乙型肝炎病毒相关急性肝衰竭的皮质类固醇和核苷类似物。
World J Gastroenterol. 2015 Sep 28;21(36):10485-6. doi: 10.3748/wjg.v21.i36.10485.
9
Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure.循环细胞死亡生物标志物:乙型肝炎病毒相关慢加急性肝衰竭患者预后指标的良好候选物。
Sci Rep. 2015 Sep 18;5:14240. doi: 10.1038/srep14240.
10
Expression of serum sCD163 in patients with liver diseases and inflammatory disorders.血清可溶性CD163在肝病和炎症性疾病患者中的表达。
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8419-25. eCollection 2015.

基于真实世界临床数据的“中医调控肝再生”治疗方案降低乙肝相关肝衰竭患者死亡率的研究

The "Traditional Chinese medicine regulating liver regeneration" treatment plan for reducing mortality of patients with hepatitis B-related liver failure based on real-world clinical data.

作者信息

Dai Ling, Gao Xiang, Ye Zhihua, Li Hanmin, Yao Xin, Lu Dingbo, Wu Na

机构信息

Institute of Liver Diseases, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.

Institute of Basic Theory of Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, 430074, China.

出版信息

Front Med. 2021 Jun;15(3):495-505. doi: 10.1007/s11684-020-0790-9. Epub 2021 Jan 12.

DOI:10.1007/s11684-020-0790-9
PMID:33433899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7801774/
Abstract

On the basis of real-world clinical data, the study aimed to explore the effect and mechanisms of the treatment plan of "traditional Chinese medicine (TCM) regulating liver regeneration." A total of 457 patients with HBV-related liver failure were retrospectively collected. The patients were divided into three groups: the modern medicine control group (MMC group), patients treated with routine medical treatment; the control group combining traditional Chinese and Western medicine (CTW), patients treated with routine medical treatment plus the common TCM formula; and the treatment group of "TCM regulating liver regeneration" (RLR), patients treated with both routine medical treatment and the special TCM formula of RLR. After 8 weeks of treatment, the mortality of patients in the RLR group (12.31%) was significantly lower than those in the MMC (50%) and CTW (29.11%) groups. Total bilirubin level significantly decreased and albumin increased in the RLR group when compared with the MMC and CTW groups (P < 0.05). In addition, there were significant differences in the expression of several cytokines related to liver regeneration in the RLR group compared with the MMC group. RLR treatment can decrease jaundice, improve liver function, and significantly reduce the mortality in patients with HBV-related liver failure. The mechanism may be related to the role of RLR treatment in influencing cytokines related to liver regeneration.

摘要

基于真实世界临床数据,本研究旨在探讨“中医调肝复元”治疗方案的疗效及机制。回顾性收集了457例HBV相关肝衰竭患者。将患者分为三组:现代医学对照组(MMC组),采用常规药物治疗;中西医结合对照组(CTW),采用常规药物治疗加常用中药方剂;“中医调肝复元”治疗组(RLR),采用常规药物治疗加RLR专用中药方剂。治疗8周后,RLR组患者死亡率(12.31%)显著低于MMC组(50%)和CTW组(29.11%)。与MMC组和CTW组相比,RLR组总胆红素水平显著降低,白蛋白水平升高(P<0.05)。此外,与MMC组相比,RLR组中几种与肝再生相关的细胞因子表达存在显著差异。RLR治疗可降低黄疸,改善肝功能,并显著降低HBV相关肝衰竭患者的死亡率。其机制可能与RLR治疗对肝再生相关细胞因子的影响有关。